Search results for "SCHEDULE"

showing 10 items of 567 documents

Fabry disease: enzyme replacement therapy

2003

Fabry disease is a multisystem disorder associated with wide variability in clinical expression. Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of alpha-galactosidase A. The enzyme defect leads to the systemic accumulation of glycosphingolipids with alpha-galactosyl moieties consisting predominantly of globotriaosylceramide, galabiosylceramide and two additional glycosphingolipids. Four hemizygotes patients with a family history of Fabry disease and deficiency of the enzyme alpha-galactosidase A were selected. Each patient received purified alpha-galactosidase by intravenous infusion (0.2 mg/kg). The infusion was administered every 2 weeks, for 40 min, for a …

Malemedicine.medical_specialtyGlobotriaosylceramideRenal functionVasomotionCorneal dystrophyDermatologyRisk AssessmentGastroenterologyDrug Administration ScheduleSampling Studieschemistry.chemical_compoundInternal medicineHumansMedicineFamily historyInfusions IntravenousDose-Response Relationship Drugbusiness.industryBiopsy NeedleOutcome measuresEnzyme replacement therapymedicine.diseaseImmunohistochemistryFabry diseaseTreatment OutcomeInfectious DiseasesEndocrinologychemistryalpha-GalactosidaseFabry DiseaseFemalebusinessFollow-Up StudiesJournal of the European Academy of Dermatology and Venereology
researchProduct

Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-[alpha]2b: A Randomized Trial

2009

BACKGROUND Many patients with chronic hepatitis C have not responded to therapy with pegylated interferon plus ribavirin. OBJECTIVE To evaluate use of peginterferon-alpha2a plus ribavirin to re-treat nonresponders to peginterferon-alpha2b plus ribavirin. DESIGN Randomized, parallel-group trial conducted between September 2003 and February 2007. Patients and researchers were not blinded to intervention assignment. Random assignment was centralized, computer-generated, and stratified by geographic region, hepatitis C virus (HCV) genotype, and histologic diagnosis. SETTING 106 international centers. PATIENTS 950 nonresponders to 12 or more weeks of therapy with peginterferon-alpha2b plus ribav…

Malemedicine.medical_specialtyHepatitis C virusAlpha interferonHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyDrug Administration SchedulePolyethylene Glycolslaw.inventionchemistry.chemical_compoundDouble-Blind MethodRandomized controlled triallawPegylated interferonInternal medicineRibavirinInternal Medicineretreatment non responder hepatitis CHumansMedicineTreatment FailureNot evaluatedbusiness.industryRibavirinInterferon-alphavirus diseasesGeneral MedicineHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesSurgerychemistryRetreatmentRNA ViralDrug Therapy CombinationFemalebusinessViral loadmedicine.drug
researchProduct

Hypertonic saline solution and decompressive craniectomy for treatment of intracranial hypertension in pediatric severe traumatic brain injury.

2002

Experimental data 8 –11 and first clinical results in adults 12,13 suggest that hypertonic saline ( 1.0) may be highly effective in lowering ICP even when mannitol has lost its therapeutic potential after prolonged and repeated use. In children, only limited experience exists with the use of hypertonic saline solutions: a randomized prospective study in children with severe head injury compared the effects on ICP (increased to 15–20 mm Hg) of isotonic (0.9% NaCl) and hypertonic (3% NaCl) saline injections, demonstrating a beneficial effect of the hypertonic solution. 14 Another prospective randomized trial compared the effects of continuous infusion of either lactated Ringer’s solution (277…

Malemedicine.medical_specialtyIntracranial PressureTraumatic brain injurymedicine.medical_treatmentBrain damageCritical Care and Intensive Care MedicineDrug Administration ScheduleInjury Severity ScorePreoperative CaremedicineHumansChildInfusions IntravenousSalineOsmolePostoperative CareSaline Solution Hypertonicbusiness.industryHead injurySodiumGlasgow Coma ScaleAccidents Trafficmedicine.diseaseDecompression SurgicalHypertonic salineSurgeryAnesthesiaBrain InjuriesSurgeryDecompressive craniectomyAccidental Fallsmedicine.symptomIntracranial HypertensionbusinessTomography X-Ray ComputedCraniotomyThe Journal of trauma
researchProduct

The Oxidative Stress Concept of Nitrate Tolerance and the Antioxidant Properties of Hydralazine

2005

The hemodynamic and anti-ischemic effects of nitroglycerin (NTG) are rapidly blunted as a result of the development of nitrate tolerance. With initiation of NTG therapy, it is possible to detect neurohormonal activation and intravascular volume expansion. These so-called pseudotolerance mechanisms may compromise the vasodilatory effects of NTG. Long-term nitrate treatment also is associated with decreased vascular responsiveness caused by changes in intrinsic mechanisms of the tolerant vasculature itself. According to the oxidative stress concept, increased vascular superoxide (O 2 − ) production and an increased sensitivity to vasoconstrictors secondary to activation of protein kinase C co…

Malemedicine.medical_specialtyMaximum Tolerated Dosegenetic structuresDrug ResistanceMyocardial IschemiaPharmacologyCoronary Angiographymedicine.disease_causeSeverity of Illness IndexDrug Administration ScheduleNitric oxideNitroglycerinchemistry.chemical_compoundInternal medicinemedicineAnimalsHumansDrug Interactionschemistry.chemical_classificationClinical Trials as TopicReactive oxygen speciesDose-Response Relationship Drugbusiness.industryHydralazineHydralazineLong-Term Careeye diseasesDisease Models AnimalOxidative StresschemistryHeart Function TestsExercise TestCardiologyFemaleVascular ResistanceEndothelium Vascularsense organsSodium nitroprussideCardiology and Cardiovascular MedicineSoluble guanylyl cyclasebusinessNicotinamide adenine dinucleotide phosphatePeroxynitriteOxidative stressmedicine.drugThe American Journal of Cardiology
researchProduct

Late onset administration of oral antioxidants prevents age-related loss of motor co-ordination and brain mitochondrial DNA damage.

1999

We have studied the effect of aging on brain glutathione redox ratio, on brain mitochondrial DNA damage and on motor co-ordination in mice and the possible protective role of late onset administration of sulphur-containing antioxidants. Glutathione redox ratios change to a more oxidized state in whole brain with aging but the changes are much more pronounced when this ratio is measured in brain mitochondria. The levels of 8-oxo-7,8-dihydro-2 '-deoxyguanosine in mitochondrial DNA are much higher in the brain of old animals than in those of young ones. Late onset oral administration of sulphur-containing antioxidants partially prevents oxidation of mitochondrial glutathione and DNA. There is …

Malemedicine.medical_specialtyMitochondrial DNAAgingAdministration OralLate onsetMice Inbred StrainsBiologyMotor Activitymedicine.disease_causeBiochemistryRedoxDNA MitochondrialAntioxidantsDrug Administration Schedulechemistry.chemical_compoundMiceOral administrationInternal medicineAge relatedmedicineAnimalsPostural BalanceAlanineBrainDeoxyguanosineGeneral MedicineGlutathioneMolecular biologyGlutathioneThiazolesEndocrinologychemistry8-Hydroxy-2'-DeoxyguanosineOxidation-ReductionOxidative stressDNASulfurDNA DamageFree radical research
researchProduct

Oxidative Inhibition of the Mitochondrial Aldehyde Dehydrogenase Promotes Nitroglycerin Tolerance in Human Blood Vessels

2007

Objectives We tested the hypothesis of whether an inhibition of the nitroglycerin (GTN) bioactivating enzyme mitochondrial aldehyde dehydrogenase (ALDH-2) contributes to GTN tolerance in human blood vessels. Background The hemodynamic effects of GTN are rapidly blunted by the development of tolerance, a phenomenon associated with increased formation of reactive oxygen species (ROS). Recent studies suggest that ROS-induced inhibition of ALDH-2 accounts for tolerance in animal models. Methods Segments of surgically removed arteria mammaria and vena saphena from patients undergoing coronary bypass surgery were used to examine the vascular responsiveness to GTN and the endothelium-dependent vas…

Malemedicine.medical_specialtyNitric Oxide Synthase Type IIIVasodilator AgentsMyocardial InfarctionAldehyde dehydrogenaseVasodilationPharmacologyDrug Administration ScheduleTissue Culture TechniquesNitroglycerinIn vivoEnosmedicineHumansSaphenous VeinEndothelial dysfunctionMammary ArteriesAgedbiologybusiness.industryAldehyde Dehydrogenase MitochondrialDrug ToleranceAldehyde Dehydrogenasemedicine.diseasebiology.organism_classificationAcetylcholineSurgeryOxidative Stressmedicine.anatomical_structureCirculatory systemcardiovascular systembiology.proteinFemaleAnimal studiesbusinessCardiology and Cardiovascular Medicinecirculatory and respiratory physiologyBlood vesselJournal of the American College of Cardiology
researchProduct

Post-Stroke Cognitive Impairment: High Prevalence and Determining Factors in a Cohort of Mild Stroke

2014

BACKGROUND Because of the aging population and a rise in the number of stroke survivors, the prevalence of post-stroke cognitive impairment (PSCI) is increasing. OBJECTIVE To identify the factors associated with 3-month PSCI. METHODS All consecutive stroke patients without pre-stroke dementia, mild cognitive disorders, or severe aphasia hospitalized in the Neurology Department of Dijon, University Hospital, France (November 2010 - February 2012) were included in this prospective cohort study. Demographics, vascular risk factors, and stroke data were collected. A first cognitive evaluation was performed during the hospitalization using the Mini-Mental State Exam (MMSE) and the Montreal Cogni…

Malemedicine.medical_specialtyObservationNeuropsychological TestsCohort StudiesDiabetes mellitusAphasiaInternal medicinePrevalenceHumansMedicineDementiaProspective cohort studyStrokeAgedAged 80 and overbusiness.industryGeneral NeuroscienceAge FactorsMontreal Cognitive AssessmentCognitionGeneral MedicineMiddle Agedmedicine.diseaseStrokePsychiatry and Mental healthClinical PsychologyCohortFemaleGeriatrics and Gerontologymedicine.symptomCognition DisordersMental Status SchedulebusinessJournal of Alzheimer's Disease
researchProduct

Fatty Acid Profiles in Demented Patients: Identification of Hexacosanoic Acid (C26:0) as a Blood Lipid Biomarker of Dementia

2014

Background: Several lipid metabolism alterations have been described in the brain and plasma of Alzheimer’s disease (AD) patients, suggesting a relation between lipid metabolism alteration and dementia. 15 16 Objective: We attempted to identify blood fatty acids as biomarkers of dementia. 17 Methods: Fatty acid profiles were established using gas chromatography with or without mass spectrometry on matched plasma and red blood cells (RBCs) of demented patients diagnosed with AD, vascular dementia, or other dementia, and compared with a control group of elderly individuals. The severity of dementia was evaluated with the Mini-Mental State Examination test. 18 19 20 Results: Fatty acid analysi…

Malemedicine.medical_specialtyPathologyChromatography GasErythrocytesBlood lipidsNeuropsychological TestsBiologyMass Spectrometrychemistry.chemical_compoundInternal medicinemedicineHumansDementiaVascular dementiaAgedAged 80 and overchemistry.chemical_classificationFatty acid metabolismGeneral NeuroscienceFatty AcidsFatty acidLipid metabolismGeneral MedicineMiddle AgedPeroxisomemedicine.diseasePsychiatry and Mental healthClinical PsychologyEndocrinologyROC CurvechemistryBiomarker (medicine)DementiaFemaleGeriatrics and GerontologyMental Status ScheduleJournal of Alzheimer's Disease
researchProduct

How to treat tumefactive demyelinating disease?

2013

Glioma-like inflammatory demyelinating lesions can be found in patients with pre-diagnosed multiple sclerosis, but they have also been described as an isolated disease entity. The initial diagnostic work-up usually includes a biopsy for histopathological analysis. However, even after unambiguous histopathologic classification, tumefactive lesions pose a therapeutic challenge. Until now, there have been no guidelines on how to treat patients with these rare and extreme lesion phenotypes. Here we report a patient with a relapsing unifocal tumefactive demyelinating lesion. The patient initially showed a good response to steroid treatment, with full clinical recovery. However, after relapse of…

Malemedicine.medical_specialtyPathologyTime FactorsBiopsymedicine.medical_treatmentDrug Administration ScheduleLesionRecurrenceInduction therapyBiopsymedicineDemyelinating diseaseHumansIn patientmedicine.diagnostic_testDrug Substitutionbusiness.industryMultiple sclerosisImmunosuppressionMiddle Agedmedicine.diseaseMagnetic Resonance ImagingRegimenTreatment OutcomeNeurologyDrug Therapy CombinationSteroidsNeurology (clinical)Radiologymedicine.symptombusinessImmunosuppressive AgentsDemyelinating DiseasesMultiple Sclerosis Journal
researchProduct

Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2) : a multinational, multicentre, single-ar…

2021

BACKGROUND: Current guidelines recommend a risk-adjusted treatment strategy for the management of acute pulmonary embolism. This is a particular patient category for whom optimal treatment (anticoagulant treatment, reperfusion strategies, and duration of hospitalisation) is currently unknown. We investigated whether treatment of acute intermediate-risk pulmonary embolism with parenteral anticoagulation for a short period of 72 h, followed by a switch to a direct oral anticoagulant (dabigatran), is effective and safe. METHODS: We did a multinational, multicentre, single-arm, phase 4 trial at 42 hospitals in Austria, Belgium, France, Germany, Italy, Netherlands, Romania, Slovenia, and Spain. …

Malemedicine.medical_specialtyPopulationAdministration OralHemorrhage030204 cardiovascular system & hematologyDrug Administration ScheduleDabigatran03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumans030212 general & internal medicineeducationAgedAged 80 and overeducation.field_of_studyRIGHT-VENTRICULAR DYSFUNCTION VENOUS THROMBOEMBOLISM DABIGATRAN MANAGEMENT WARFARIN HOSPITALIZATION RATIONALE HEPARIN DESIGNHeparinbusiness.industryAnticoagulantsVenous ThromboembolismHematologyGuidelineHeparinMiddle AgedInterim analysismedicine.diseaseThrombosisDabigatran3. Good healthPulmonary embolismClinical trialTreatment OutcomeFemalePulmonary EmbolismbusinessFollow-Up Studiesmedicine.drug
researchProduct